# KEYTRUDA QLEX

NDC: 0006-5083
Generic name: pembrolizumab and berahyaluronidase alfa-pmph
Labeler / Manufacturer: Merck Sharp & Dohme LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20250919

FDA application: BLA761467

## Active ingredients

- BERAHYALURONIDASE ALFA: 2000 U/mL
- PEMBROLIZUMAB: 165 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0006-5083"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0006-5083
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=097d166f-b73b-41d3-9b37-7653cd2a0c41